High Sick Leave Among Longterm Cancer Survivors

According to findings by researcher Steffen Torp and colleagues from Vestfold University College in Norway and published in the Journal of Cancer Survivorship, in the five years following diagnosis, cancer survivors take sick leave from their jobs at a significantly higher clip than co-workers without a history of cancer.

The team of researchers looked at data from the Norwegian population-based registries and the Cancer Registry of Norway for over 2,000 adults previously diagnosed with invasive cancer. For a control group, they used 3,240 carefully matched 'healthy' individuals.

What they determind was that long-term cancer survivors tended to take substantially more sick leave during those five years. Three quarters of the cancer survivors understandably took some sick leave in the first year following their diagnosis; over the next four years, 23 percent of men and 31 percent of women recovering from cancer took sick leave, compared to approximately 18 percent of men and 27 percent of women in the control group.

Of note, cancer type or severity of the disease was not the most important predictor of sick leave. Rather, socio-demographic factors played a bigger role, such as being single with children, education, working in the health and social care fields, or having taken sick leave the year before diagnosis.

Most cancer survivors return to work, and most experts regard returning to work as a crucial aspect of one's psychological recovery from cancer, as well as one's economic recovery from the disease.

"Employed long-term cancer survivors may struggle with health impairments or reduced work ability five years after diagnosis," the authors wrote. "A socioeconomic and work environmental perspective seems necessary for occupational rehabilitation and the health and safety of cancer survivors, in order to reduce the rate of sick leave in this group."

Source: ecancer

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap